Eosinophilic esophagitis.
Eosinophilic esophagitis is increasingly recognized in adults. The diagnosis is based on the presence of both typical symptoms and pathologic findings on esophageal biopsy. Patients usually present with dysphagia, food impaction and/or reflux-like symptoms, and biopsy of the esophagus shows more than 15 eosinophils per high-power field. In addition, it is essential to exclude the presence of known causes of tissue eosinophilia such as gastroesophageal reflux disease, infections, malignancy, collagen vascular diseases, hypersensitivity, and inflammatory bowel disease. There are no standardized protocols for the therapy of eosinophilic esophagitis. A variety of therapeutic approaches including acid suppression, dietary modifications, topical corticosteroids and endoscopic dilation can be used alone or in combination.
Gupte
Anand R
AR
Department of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, Florida 32610, USA.
Draganov
Peter V
PV
D000328:Adult; D001688:Biological Products / Q000627:therapeutic use; D004106:Dilatation; D004802:Eosinophilia / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D004941:Esophagitis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D004945:Esophagoscopy; D005526:Food, Formulated; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D013256:Steroids / Q000627:therapeutic use
D001688:Biological Products; D007155:Immunologic Factors; D020024:Leukotriene Antagonists; D054328:Proton Pump Inhibitors; D013256:Steroids